← Russell 3000 cross-section

ANIK Anika Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$290m
Revenue TTM
$121m
Net income TTM
$-4m
Free cash flow
$1m
Composite score
58.9
Sector rank
#2681

Valuation

P / E
EV / EBITDA
434.3
EV / sales
2.1
FCF yield
0.19%
Earnings yield vs 10-yr
-6.04pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-3.1%
EBITDA margin
0.5%
ROE
-2.8%
ROIC
-5.2%
Revenue growth
31.4%

Insider activity, last 90 days

Net open-market
$0.04m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Results of Operations Three and Six Months Ended June 30, 2026, Compared to Three and Six Months Ended June 30, 2025 Revenue The following table presents revenue by product family for the three and six-month periods ended June 30, 2026, and 2025: Revenue for the three- and six- month periods ended June 30, 2026, was $32.6 million and $62.2 million, respectively. Revenue increased $4.4 million and $7.8 million, or 16% and 14%, for the three- and six- month periods ended June 30, 2026, compared to the same periods in 2025, respectively. …Anika Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →